FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2175655704> ?p ?o ?g. }

• W2175655704 endingPage "588" @default.
• W2175655704 startingPage "584" @default.
• W2175655704 abstract "Allogeneic stem cell transplantation (allo-HCT) represents the most effective immunotherapy for acute myeloid leukemia (AML) and myeloid malignancies. However, disease relapse remains the most common cause of treatment failure. By performing a second allo-HCT, durable remission can be achieved in some patients. However, a second allo-HCT is of no benefit for the majority of patients, so this approach requires further understanding. We present a retrospective cohort of 116 patients diagnosed with AML, myelodysplastic syndromes, and myeloproliferative disorders who consecutively underwent a second allo-HCT for disease relapse. The median age was 38 years (range, 4 to 69 years). Sixty-three patients were alive at last follow-up. The median follow-up of the whole cohort was 193 days (range, 2 to 6724 days) and the median follow-up of survivors was 1628 days (range, 52 to 5518 days). Overall survival (OS) at 5 years was 32% (SE ± 4.7%). Multivariate analysis identified active disease status (P < .001) and second allo-HCT < 430 days (the median of the time to second transplantation) after the first transplantation (P < .001) as factors for poor prognosis, whereas the use of an HLA-identical sibling donor for the second allo-HCT was identified as a good prognostic factor (P < .05) for OS. The use of myeloablative conditioning (P = .01), active disease (P = .02), and a donor other than an HLA-identical sibling (others versus HLA-identical siblings) (P = .009) were factors statistically significant for nonrelapse mortality in multivariate analysis. Time to second transplantation was statistically significant (P = .001) in the relapse multivariate analysis, whereas multivariate analysis identified active disease status (P < .001) and time to second transplantation (P < .001) as poor prognosis factors for disease-free survival. This study confirms active disease and early relapse as dismal prognostic factors for a second allo-HCT. Using a different donor at second allo-HCT did not appear to change outcome, but using an HLA-identical sibling donor for a second transplantation appears to be associated with better survival. Further studies are warranted." @default.
• W2175655704 created "2016-06-24" @default.
• W2175655704 creator A5002845944 @default.
• W2175655704 creator A5006549736 @default.
• W2175655704 creator A5008597414 @default.
• W2175655704 creator A5011772396 @default.
• W2175655704 creator A5014668375 @default.
• W2175655704 creator A5017341923 @default.
• W2175655704 creator A5023787291 @default.
• W2175655704 creator A5025361225 @default.
• W2175655704 creator A5025894116 @default.
• W2175655704 creator A5029260153 @default.
• W2175655704 creator A5037662864 @default.
• W2175655704 creator A5039749768 @default.
• W2175655704 creator A5040307230 @default.
• W2175655704 creator A5045690141 @default.
• W2175655704 creator A5056515068 @default.
• W2175655704 creator A5068540124 @default.
• W2175655704 creator A5074445253 @default.
• W2175655704 creator A5075722788 @default.
• W2175655704 creator A5076623303 @default.
• W2175655704 creator A5084156876 @default.
• W2175655704 creator A5087171473 @default.
• W2175655704 creator A5089964057 @default.
• W2175655704 date "2016-03-01" @default.
• W2175655704 modified "2023-10-18" @default.
• W2175655704 title "Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico" @default.
• W2175655704 cites W1863755384 @default.
• W2175655704 cites W1919339218 @default.
• W2175655704 cites W1961045948 @default.
• W2175655704 cites W1965732057 @default.
• W2175655704 cites W1989670388 @default.
• W2175655704 cites W2009379600 @default.
• W2175655704 cites W2011489303 @default.
• W2175655704 cites W2016552170 @default.
• W2175655704 cites W2021412223 @default.
• W2175655704 cites W2036116596 @default.
• W2175655704 cites W2050519979 @default.
• W2175655704 cites W2058833974 @default.
• W2175655704 cites W2059380567 @default.
• W2175655704 cites W2109948637 @default.
• W2175655704 cites W2112998845 @default.
• W2175655704 cites W2128499479 @default.
• W2175655704 cites W2133384656 @default.
• W2175655704 cites W2164078870 @default.
• W2175655704 cites W2257559310 @default.
• W2175655704 cites W2402799752 @default.
• W2175655704 cites W2416148102 @default.
• W2175655704 cites W44995847 @default.
• W2175655704 doi "https://doi.org/10.1016/j.bbmt.2015.11.012" @default.
• W2175655704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26631751" @default.
• W2175655704 hasPublicationYear "2016" @default.
• W2175655704 type Work @default.
• W2175655704 sameAs 2175655704 @default.
• W2175655704 citedByCount "45" @default.
• W2175655704 countsByYear W21756557042016 @default.
• W2175655704 countsByYear W21756557042017 @default.
• W2175655704 countsByYear W21756557042018 @default.
• W2175655704 countsByYear W21756557042019 @default.
• W2175655704 countsByYear W21756557042020 @default.
• W2175655704 countsByYear W21756557042021 @default.
• W2175655704 countsByYear W21756557042022 @default.
• W2175655704 countsByYear W21756557042023 @default.
• W2175655704 crossrefType "journal-article" @default.
• W2175655704 hasAuthorship W2175655704A5002845944 @default.
• W2175655704 hasAuthorship W2175655704A5006549736 @default.
• W2175655704 hasAuthorship W2175655704A5008597414 @default.
• W2175655704 hasAuthorship W2175655704A5011772396 @default.
• W2175655704 hasAuthorship W2175655704A5014668375 @default.
• W2175655704 hasAuthorship W2175655704A5017341923 @default.
• W2175655704 hasAuthorship W2175655704A5023787291 @default.
• W2175655704 hasAuthorship W2175655704A5025361225 @default.
• W2175655704 hasAuthorship W2175655704A5025894116 @default.
• W2175655704 hasAuthorship W2175655704A5029260153 @default.
• W2175655704 hasAuthorship W2175655704A5037662864 @default.
• W2175655704 hasAuthorship W2175655704A5039749768 @default.
• W2175655704 hasAuthorship W2175655704A5040307230 @default.
• W2175655704 hasAuthorship W2175655704A5045690141 @default.
• W2175655704 hasAuthorship W2175655704A5056515068 @default.
• W2175655704 hasAuthorship W2175655704A5068540124 @default.
• W2175655704 hasAuthorship W2175655704A5074445253 @default.
• W2175655704 hasAuthorship W2175655704A5075722788 @default.
• W2175655704 hasAuthorship W2175655704A5076623303 @default.
• W2175655704 hasAuthorship W2175655704A5084156876 @default.
• W2175655704 hasAuthorship W2175655704A5087171473 @default.
• W2175655704 hasAuthorship W2175655704A5089964057 @default.
• W2175655704 hasBestOaLocation W21756557041 @default.
• W2175655704 hasConcept C126322002 @default.
• W2175655704 hasConcept C138496976 @default.
• W2175655704 hasConcept C141071460 @default.
• W2175655704 hasConcept C143998085 @default.
• W2175655704 hasConcept C15744967 @default.
• W2175655704 hasConcept C167135981 @default.
• W2175655704 hasConcept C2776194465 @default.
• W2175655704 hasConcept C2777408962 @default.
• W2175655704 hasConcept C2778729363 @default.
• W2175655704 hasConcept C2779134260 @default.
• W2175655704 hasConcept C2779282312 @default.

• next